Next February 28th is Rare Disease Day. To mark this special date, Teamit will participate in several events organised by EURORDIS, the European Organisation for Rare Diseases, with whom we are closely collaborating in far-reaching projects as REMEDi4ALL.
Eva Molero and Gisela Pairó, Teamit CEO and Head of Communications respectively, will join the Black Pearl Awards in Brussels next 21st of February. This long-established event, which can also be followed online, recognises each year the outstanding achievements and work of those who have made a difference for the rare disease community. Molero has already participated in past editions of the Black Pearl Awards which brings together hundreds of persons living with a rare disease, patient advocates, policy makers, including representatives from the European Parliament and Commission, researchers, healthcare professionals, industry representatives, and more. Lines are open to vote for your favourite social media campaign and best photo.
Contributing to advance research on rare diseases
Teamit is already playing a part in rare diseases research as partners in REMEDi4ALL and EU-PEARL projects. REMEDi4ALL, a Horizon Europe initiative kicked off last year to streamline and advance medicine repurposing. Precisely, finding new uses for existing medicines, holds an enormous potential to develop new treatment options for rare diseases. In fact, the project is already focusing on a rare and ultra rare disease, Osteogenesis Imperfecta and Multiple Sulfatase Deficiency, to test a cutting-edge platform to repurpose already known drugs.
EU-PEARL, a project funded by the Innovative Medicines Initiative, has developed a cutting edge framework to set up and conduct platform trials. In this type of clinical trials, several drugs under investigation can be tested simultaneously, potentially shortening the timeline to develop and bring to market new medicines for patients. Neurofibromatosis, a rare condition affecting around 2 million people worldwide, is one of the diseases EU-PEARL has focused on to design a ready to operate adaptive platform trial. Finally, Teamit also closely follows up the “Rare Disease Moonshot” initiative that aims to boost research and development into rare and paediatric diseases through a range of public-private partnerships.
Follow us on Twitter and LinkedIn to keep up with latest news.
